Rational Design Platform to Generate Dual-Acting Kinase and Bromodomain Inhibitors

Science-Business eXchange
doi 10.1038/scibx.2014.357
Full Text
Abstract

Available in full text

Date
Authors

Unknown

Publisher

Springer Science and Business Media LLC

Related search

Rational Drug Design of Axl Tyrosine Kinase Type I Inhibitors as Promising Candidates Against Cancer

Frontiers in Chemistry
Chemistry
2020English

Rational Design of Peptide-Based HIV Proteinase Inhibitors

Science
MultidisciplinaryPhilosophy of ScienceHistory
1990English

Using Dopamine Research to Generate Rational Cannabinoid Drug Policy

Drug Testing and Analysis
Environmental ChemistryAnalytical ChemistrySpectroscopyPharmaceutical Science
2012English

Bromodomain Inhibitors in Degenerative Eye Disease; An Alternative to VEGF Inhibitors in Macular Degeneration?

World Journal of Ophthalmology & Vision Research
2020English

BET Bromodomain Inhibitors Synergize With ATR Inhibitors in Melanoma in Melanoma

Cell Death and Disease
Molecular NeuroscienceImmunologyCell BiologyCancer ResearchCellularMedicine
2017English

Electrophilic Fragment-Based Design of Reversible Covalent Kinase Inhibitors

Journal of the American Chemical Society
BiochemistryColloidCatalysisChemistrySurface Chemistry
2013English

Applying 89Zr-Transferrin to Study the Pharmacology of Inhibitors to BET Bromodomain Containing Proteins

English

Rational Design of Berberine-Based FtsZ Inhibitors With Broad-Spectrum Antibacterial Activity

PLoS ONE
Multidisciplinary
2014English

Identification of New Snake Venom Metalloproteinase Inhibitors Using Compound Screening and Rational Peptide Design

ACS Medicinal Chemistry Letters
Organic ChemistryBiochemistryDrug Discovery
2012English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy